Catalyst Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare neurological disorders.
This is a list of the 10 largest Catalyst Pharmaceuticals shareholders as of 9/14/2023.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare neuromuscular and neurological diseases.
Catalyst Pharmaceuticals is primarily known for its drug Firdapse (amifampridine phosphate), which is used for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder that affects the neuromuscular junction.
Firdapse was approved by the U.S. Food and Drug Administration (FDA) in 2018 as the first and only approved treatment for LEMS.
It works by increasing the release of acetylcholine, a neurotransmitter that plays a crucial role in muscle contraction.
These top shareholders in Catalyst Pharmaceuticals are a mix of institutional investors, investment management firms, and asset managers.
Together, they own a significant portion of the company and have a significant influence on its operations and strategic decisions.